company background image
IBNSINA logo

IBN SINA Pharmaceutical Industry DSE:IBNSINA Stock Report

Last Price

৳278.40

Market Cap

৳8.7b

7D

-6.6%

1Y

-2.9%

Updated

20 Nov, 2024

Data

Company Financials +

The IBN SINA Pharmaceutical Industry PLC

DSE:IBNSINA Stock Report

Market Cap: ৳8.7b

IBNSINA Stock Overview

Produces and sells pharmaceutical drugs in Bangladesh and internationally. More details

IBNSINA fundamental analysis
Snowflake Score
Valuation4/6
Future Growth5/6
Past Performance2/6
Financial Health5/6
Dividends4/6

The IBN SINA Pharmaceutical Industry PLC Competitors

Price History & Performance

Summary of all time highs, changes and price drops for IBN SINA Pharmaceutical Industry
Historical stock prices
Current Share Price৳278.40
52 Week High৳384.80
52 Week Low৳223.50
Beta0.18
11 Month Change-7.88%
3 Month Change-6.45%
1 Year Change-2.86%
33 Year Change3.42%
5 Year Change17.92%
Change since IPO8,340.64%

Recent News & Updates

Recent updates

Shareholder Returns

IBNSINABD PharmaceuticalsBD Market
7D-6.6%-2.3%-0.9%
1Y-2.9%-25.3%-20.0%

Return vs Industry: IBNSINA exceeded the BD Pharmaceuticals industry which returned -25.3% over the past year.

Return vs Market: IBNSINA exceeded the BD Market which returned -20% over the past year.

Price Volatility

Is IBNSINA's price volatile compared to industry and market?
IBNSINA volatility
IBNSINA Average Weekly Movement6.5%
Pharmaceuticals Industry Average Movement8.3%
Market Average Movement7.0%
10% most volatile stocks in BD Market9.3%
10% least volatile stocks in BD Market3.9%

Stable Share Price: IBNSINA has not had significant price volatility in the past 3 months compared to the BD market.

Volatility Over Time: IBNSINA's weekly volatility (6%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
19834,200A. K. Sadrul Islamwww.ibnsinapharma.com

The IBN SINA Pharmaceutical Industry PLC produces and sells pharmaceutical drugs in Bangladesh and internationally. The company provides its products in various forms, such as solid dosage forms consisting of tablets and capsules; parenteral products covering ampoules and vials; liquid dosage forms comprising syrups, solutions, suspensions, and powder for suspension (dry syrups); and sterile ophthalmic products, creams, ointments, gels, eye drops and sachet, etc. It also offers various therapeutic products, including analgesic and anti-inflammatory, anti-allergic-occular, anti-arthritis supplement, anti-asthmatic, anti-emetic, anti-fibrinolytic, anti-fungal, anti-glucoma, anti-histamine, anti-malarial, anti-melasma, anti-neuropathic, anti-protozoal, anti-spasmodic, anti-ulcerant, antibacterial, antibiotic, anticataract, anti-diabetic, antigout, anti-helmintic, antimigraine agent, antisecretory, antivertigo agent, and antiviral products. In addition, the company’s therapeutic products comprise antibiotic and steroid, antibiotic-occular, antifungal-occular, antiviral-occular, anxiolytic and antidepressant, aromatase inhibitor, bile acid, bisphosphonates, calcium supplement, cardiovascular preparation, cholinesterase inhibitor, corticosteroid, cough expectorant, dry eye syndrome, gastroprokinetic agent, haematinic/vitamin and mineral, hand rub, hormone products, intestinal anti-inflammatory, laxative, multivitamin and multi-minerals, muscle relaxant, mydriatic agents, nasal decongestant, neuroleptic, nootropic, NSAIDS, NSAIDS-occular, ORS, steroid-occular, topical, urological preparation, urinary incontinence, and sodium-glucose co-transporter inhibitor products.

The IBN SINA Pharmaceutical Industry PLC Fundamentals Summary

How do IBN SINA Pharmaceutical Industry's earnings and revenue compare to its market cap?
IBNSINA fundamental statistics
Market cap৳8.70b
Earnings (TTM)৳592.31m
Revenue (TTM)৳11.23b

14.7x

P/E Ratio

0.8x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
IBNSINA income statement (TTM)
Revenue৳11.23b
Cost of Revenue৳6.78b
Gross Profit৳4.45b
Other Expenses৳3.86b
Earnings৳592.31m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)18.96
Gross Margin39.60%
Net Profit Margin5.27%
Debt/Equity Ratio44.3%

How did IBNSINA perform over the long term?

See historical performance and comparison

Dividends

2.3%

Current Dividend Yield

33%

Payout Ratio

Does IBNSINA pay a reliable dividends?

See IBNSINA dividend history and benchmarks
When do you need to buy IBNSINA by to receive an upcoming dividend?
IBN SINA Pharmaceutical Industry dividend dates
Ex Dividend DateOct 28 2024
Dividend Pay DateDec 24 2024
Days until Ex dividend24 days
Days until Dividend pay date33 days

Does IBNSINA pay a reliable dividends?

See IBNSINA dividend history and benchmarks